These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
382 related articles for article (PubMed ID: 17375074)
1. Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines. Koya RC; Kimura T; Ribas A; Rozengurt N; Lawson GW; Faure-Kumar E; Wang HJ; Herschman H; Kasahara N; Stripecke R Mol Ther; 2007 May; 15(5):971-80. PubMed ID: 17375074 [TBL] [Abstract][Full Text] [Related]
2. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645 [TBL] [Abstract][Full Text] [Related]
3. Transfection of immature murine bone marrow-derived dendritic cells with the granulocyte-macrophage colony-stimulating factor gene potently enhances their in vivo antigen-presenting capacity. Curiel-Lewandrowski C; Mahnke K; Labeur M; Roters B; Schmidt W; Granstein RD; Luger TA; Schwarz T; Grabbe S J Immunol; 1999 Jul; 163(1):174-83. PubMed ID: 10384114 [TBL] [Abstract][Full Text] [Related]
4. Programming the next generation of dendritic cells. Carroll RG; June CH Mol Ther; 2007 May; 15(5):846-8. PubMed ID: 17446871 [No Abstract] [Full Text] [Related]
5. Anti-melanoma vaccinal capacity of CD11c-positive and -negative cell populations present in GM-CSF cultures derived from murine bone marrow precursors. Campisano S; Mac Keon S; Gazzaniga S; Ruiz MS; Traian MD; Mordoh J; Wainstok R Vaccine; 2013 Jan; 31(2):354-61. PubMed ID: 23146677 [TBL] [Abstract][Full Text] [Related]
6. [Inhibiting effect of IL-10 in tumor microenvironment on anti-tumor activity of SOCS1-silenced DC vaccine]. Wang Z; You H; Song S Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Apr; 29(4):379-83. PubMed ID: 23643168 [TBL] [Abstract][Full Text] [Related]
7. Rapid and efficient generation of lentivirally gene-modified dendritic cells from DC progenitors with bone marrow stromal cells. Sumimoto H; Tsuji T; Miyoshi H; Hagihara M; Takada-Yamazaki R; Okamoto S; Ikeda Y; Takahashi T; Kawakami Y J Immunol Methods; 2002 Dec; 271(1-2):153-65. PubMed ID: 12445738 [TBL] [Abstract][Full Text] [Related]
8. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen. Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899 [TBL] [Abstract][Full Text] [Related]
9. Making dendritic cells from the inside out: lentiviral vector-mediated gene delivery of granulocyte-macrophage colony-stimulating factor and interleukin 4 into CD14+ monocytes generates dendritic cells in vitro. Koya RC; Weber JS; Kasahara N; Lau R; Villacres MC; Levine AM; Stripecke R Hum Gene Ther; 2004 Aug; 15(8):733-48. PubMed ID: 15319031 [TBL] [Abstract][Full Text] [Related]
11. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810 [TBL] [Abstract][Full Text] [Related]
12. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies. Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962 [TBL] [Abstract][Full Text] [Related]
13. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells. Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215 [TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. Klein C; Bueler H; Mulligan RC J Exp Med; 2000 May; 191(10):1699-708. PubMed ID: 10811863 [TBL] [Abstract][Full Text] [Related]
15. Lentivirus-induced 'Smart' dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma. Sundarasetty BS; Chan L; Darling D; Giunti G; Farzaneh F; Schenck F; Naundorf S; Kuehlcke K; Ruggiero E; Schmidt M; von Kalle C; Rothe M; Hoon DS; Gerasch L; Figueiredo C; Koehl U; Blasczyk R; Gutzmer R; Stripecke R Gene Ther; 2015 Sep; 22(9):707-20. PubMed ID: 25965393 [TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses. Weigel BJ; Nath N; Taylor PA; Panoskaltsis-Mortari A; Chen W; Krieg AM; Brasel K; Blazar BR Blood; 2002 Dec; 100(12):4169-76. PubMed ID: 12393694 [TBL] [Abstract][Full Text] [Related]